This post was originally published on News-medical.net
You will shortly be re-directed to the publisher's website
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a ‘magic bullet’ strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.